MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
OPKO Health Long-Term Debt 2011-2026 | OPK
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt OPKO Health
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 M | 7.73 M | 9.29 M | 205 M | 226 M | 260 M | 167 M | 135 M | 83.2 M | 124 M | 134 M | 215 M | 5.15 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 260 M | 3 M | 121 M |
Quarterly Long-Term Debt OPKO Health
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.77 M | 2.83 M | 3.53 M | 3.68 M | 4.04 M | 7.93 M | 8.5 M | 245 M | 9.29 M | 245 M | - | 230 M | 205 M | 1.67 M | 3.97 M | 3.32 M | 3.84 M | 4.01 M | 3.84 M | 3.84 M | 3.91 M | 4.09 M | 3.91 M | 3.91 M | 4.65 M | 4.65 M | 4.65 M | 4.65 M | 1.57 M | 1.57 M | 1.57 M | 1.57 M | 717 K | 717 K | 717 K | 717 K | 2.52 M | 2.52 M | 2.52 M | 2.52 M | 2.43 M | 2.43 M | 2.43 M | 2.43 M | 3.27 M | 3.27 M | 3.27 M | 3.27 M | 5.15 M | 5.15 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 245 M | 717 K | 22 M |
Long-Term Debt of other stocks in the Diagnostics research industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
15.6 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Biomerica
BMRA
|
100 K | $ 2.13 | - | $ 4.89 M |  USA |
|
Akumin
AKU
|
1.25 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
189 K | - | -8.98 % | $ 14.8 K | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
32 K | - | - | $ 562 M |  Britain |
 |
Lantheus Holdings
LNTH
|
569 M | $ 75.5 | -0.31 % | $ 5.1 B | USA |
 |
DermTech
DMTK
|
38 K | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
2.32 M | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
2.15 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
114 M | $ 455.28 | -0.36 % | $ 13.1 B | USA |
 |
Accelerate Diagnostics
AXDX
|
782 K | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
147 K | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
54.2 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
388 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
5.49 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
1.16 B | - | - | $ 10.7 B | USA |
 |
Mettler-Toledo International
MTD
|
2.09 B | $ 1 229.6 | -0.87 % | $ 25.3 B |  Schweiz |
 |
Charles River Laboratories International
CRL
|
2.14 B | $ 156.54 | -0.92 % | $ 7.76 B | USA |
 |
IQVIA Holdings
IQV
|
13.9 B | $ 165.42 | -0.95 % | $ 28.4 B | USA |
 |
Myriad Genetics
MYGN
|
120 M | $ 4.6 | -1.29 % | $ 426 M | USA |
 |
Biocept
BIOC
|
1.2 M | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
3.78 M | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
3.48 M | $ 1.25 | -14.38 % | $ 6.81 M | USA |
 |
National Research Corporation
NRC
|
75 M | $ 17.47 | -0.26 % | $ 391 M | USA |
 |
Interpace Biosciences
IDXG
|
1.18 M | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
IDEXX Laboratories
IDXX
|
375 M | $ 569.86 | -1.5 % | $ 45.8 B | USA |
 |
Illumina
ILMN
|
554 M | $ 122.99 | -0.65 % | $ 19.6 B | USA |
 |
ICON Public Limited Company
ICLR
|
3.4 B | $ 100.22 | -0.13 % | $ 8.27 B |  Irlanda |
 |
Guardant Health
GH
|
1.5 B | $ 84.35 | -0.65 % | $ 10.6 B | USA |
 |
QIAGEN N.V.
QGEN
|
1.34 B | - | - | $ 10.6 B |  Niderland |
 |
Pacific Biosciences of California
PACB
|
56.6 M | $ 1.38 | -1.08 % | $ 414 M | USA |
 |
Celcuity
CELC
|
105 M | $ 103.02 | -3.49 % | $ 4.06 B | USA |
 |
Precipio
PRPO
|
106 K | $ 26.93 | - | $ 35 M | USA |
 |
Personalis
PSNL
|
34.9 M | $ 7.71 | 1.37 % | $ 457 M | USA |
 |
Chembio Diagnostics
CEMI
|
76.7 K | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
5.08 B | $ 263.52 | -0.36 % | $ 21.9 B | USA |
 |
Motus GI Holdings
MOTS
|
1.24 M | - | -34.28 % | $ 263 K |  Israel |
 |
RadNet
RDNT
|
1.06 B | $ 60.39 | -2.19 % | $ 4.54 B | USA |
 |
ENDRA Life Sciences
NDRA
|
366 K | $ 3.41 | -2.16 % | $ 1.83 M | USA |
 |
NeoGenomics
NEO
|
342 M | $ 7.91 | -2.35 % | $ 1.01 B | USA |
 |
Agilent Technologies
A
|
2.73 B | $ 111.72 | -0.27 % | $ 34 B | USA |
 |
Natera
NTRA
|
282 M | $ 194.13 | -2.98 % | $ 19.1 B | USA |
 |
CareDx, Inc
CDNA
|
19.7 M | $ 17.24 | -1.82 % | $ 919 M | USA |
 |
Senseonics Holdings
SENS
|
35.6 M | $ 6.58 | -0.68 % | $ 275 M | USA |
 |
Castle Biosciences
CSTL
|
9.74 M | $ 25.84 | 0.35 % | $ 718 M | USA |
 |
Sotera Health Company
SHC
|
2.13 B | $ 13.77 | -0.79 % | $ 3.91 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
5.17 B | $ 194.57 | -0.54 % | $ 21.6 B | USA |
 |
DarioHealth Corp.
DRIO
|
30.7 M | $ 7.37 | -1.73 % | $ 29.4 M | Israel |